BioPharmaTrend
News
All Topics
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
  • NeuroTech
  • Interviews
  • Business Intelligence
  • Case Studies
Intelligence
  • Business Intelligence
  • Case Studies
  • Lab
  • Membership
About
  • At a Glance
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Newsletter
Login/Join
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
  • NeuroTech

  News

Agenus and Noetik Partner to Develop AI-Based Biomarkers Using Virtual Cell Models

by BiopharmaTrend   •   June 17, 2025

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# AI in Bio   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Agenus has partnered with San Francisco-based Noetik to develop AI-enabled predictive biomarkers for its lead immunotherapy regimen, botensilimab (BOT) and balstilimab (BAL). The collaboration aims to improve clinical response prediction by applying Noetik’s virtual cell foundation models directly to Agenus’ clinical dataset.

#advertisement
AI in Drug Discovery Report 2025

At the center of the effort is Noetik’s OCTO model, a 1.5 billion-parameter foundation model trained on a proprietary dataset spanning 200 million tumor and immune cells across multiple cancer types. Built as a “world model” of patient biology, it integrates spatial proteomics, transcriptomics, DNA sequencing, and pathology to simulate complex tumor behavior.

Illustration of OCTO's multimodal counterfactual simulation; Source: NOETIK

OCTO uses structured masking and visual prompting to infer biological responses to therapeutic interventions, enabling counterfactual simulations that predict how gene or protein perturbations might alter disease progression. Designed to scale and generalize, OCTO allows researchers to identify drug targets, validate biomarkers, and explore treatment strategies in silico.

Agenus’ BOT/BAL combination, targeting CTLA-4 and PD-1 pathways, has shown activity in over 1,200 patients across nine tumor types, including those traditionally resistant to immunotherapy. By identifying biomarkers predictive of response, the partnership seeks to stratify patient populations and increase the likelihood of success in pivotal trials.

Agenus retains exclusive rights to use insights from the collaboration in its clinical and commercial programs.

Topic: AI in Bio

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Newsletter
  • Business Intelligence
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Advertise
  • Lab Access
  • Lab Membership
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.